(Q39456786)

12 September 2017

title

Targeting BCL-2-like Proteins to Kill Cancer Cells (English)

1 reference

12 September 2017

Andrew W Roberts

2

0 references

Jerry Adams

object named as

Jerry M Adams

series ordinal

4

0 references

Suzanne Cory

object named as

Suzanne Cory

series ordinal

1

0 references

author name string

Peter M Colman

series ordinal

3

1 reference

12 September 2017

publication date

30 July 2016

1 reference

12 September 2017

1 reference

12 September 2017

volume

2

1 reference

12 September 2017

issue

8

1 reference

12 September 2017

page(s)

443-460

1 reference

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Targeting BCL2 for the treatment of lymphoid malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Many players in BCL-2 family affairs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Mechanisms of action of Bcl-2 family proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Chromosome 14 translocations in non-burkitt lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Induction of apoptosis in fibroblasts by c-myc protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

miR-15 and miR-16 induce apoptosis by targeting BCL2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Caenorhabditis elegans gene ced-9 protects cells from programmed cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Regulation of Bcl-2 family proteins by posttranslational modifications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Structure of Bax: coregulation of dimer formation and intracellular localization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

The Bcl-2 family: structures, interactions and targets for drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Solution structure of BID, an intracellular amplifier of apoptotic signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

The structure of a Bcl-xL/Bim fragment complex: implications for Bim function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

The functional differences between pro-survival and pro-apoptotic B cell lymphoma 2 (Bcl-2) proteins depend on structural differences in their Bcl-2 homology 3 (BH3) domains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

BID-induced structural changes in BAK promote apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bak core and latch domains separate during activation, and freed core domains form symmetric homodimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bax dimerizes via a symmetric BH3:groove interface during apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

The landscape of somatic copy-number alteration across human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

BCL-2 family antagonists for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Programmed anuclear cell death delimits platelet life span.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bcl-2 family proteins are essential for platelet survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Dysregulation of apoptosis genes in hematopoietic malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Risk categories and refractory CLL in the era of chemoimmunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Structure-guided design of a selective BCL-X(L) inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Haploinsufficiency of Bcl-x leads to male-specific defects in fetal germ cells: differential regulation of germ cell apoptosis between the sexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Direct and selective small-molecule activation of proapoptotic BAX

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Identification of an activation site in Bak and mitochondrial Bax triggered by antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Intracellular localization of the BCL-2 family member BOK and functional implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

High-Resolution Structural Characterization of a Helical α/β-Peptide Foldamer Bound to the Anti-Apoptotic Protein Bcl-xL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bcl-XL inhibits membrane permeabilization by competing with Bax.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

BAX activation is initiated at a novel interaction site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

BH3-triggered structural reorganization drives the activation of proapoptotic BAX.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Molecular details of Bax activation, oligomerization, and membrane insertion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bax forms an oligomer via separate, yet interdependent, surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Conformational changes in BAK, a pore-forming proapoptotic Bcl-2 family member, upon membrane insertion and direct evidence for the existence of BH3-BH3 contact interface in BAK homo-oligomers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

Killing cancer cells by flipping the Bcl-2/Bax switch.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.07.001

10.1016/J.TRECAN.2016.07.001

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference